The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Preliminary phase 1 results of INCB161734, a novel oral Kirsten rat sarcoma (KRAS) G12D inhibitor, as monotherapy or in combination with chemotherapy for advanced/metastatic pancreatic duct adenocarcinoma (PDAC).
 
Zev Wainberg
Consulting or Advisory Role - Alligator Bioscience; Amgen; Arcus Biosciences; Astellas Pharma; AstraZeneca/MedImmune; Bayer; Bridgebio; Bristol-Myers Squibb; Daiichi Sankyo/Astra Zeneca; EMD Serono; Ipsen; Janssen Oncology; Lilly; Merck; Merck KGaA; Novartis; Pfizer; Phanes Therapeutics; Revolution Medicines; Seagen
Research Funding - Five Prime Therapeutics (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Plexxikon (Inst)
Travel, Accommodations, Expenses - Amgen; Bayer; Lilly; Merck
 
Jason Henry
Employment - HCA Healthcare
Stock and Other Ownership Interests - HCA Healthcare
Research Funding - Abbisko (Inst); ABL Bio (Inst); accutar biotech (Inst); ADC Therapeutics (Inst); Agenus (Inst); Aileron Therapeutics (Inst); Amgen (Inst); Artios (Inst); AstraZeneca/Merck (Inst); Bicycle Therapeutics (Inst); BioAtla (Inst); Bioinvent (Inst); Biosplice (Inst); Black Diamond Therapeutics (Inst); Boehringer Ingelheim (Inst); cyteir (Inst); DaiichI Sankyo (Inst); Daiichi Sankyo/Lilly (Inst); Epizyme (Inst); Erasca, Inc (Inst); Exelixis (Inst); Fujifilm (Inst); GlaxoSmithKline (Inst); Hutchison MediPharma (Inst); Iconic Therapeutics (Inst); Iconic Therapeutics (Inst); Iconic Therapeutics (Inst); IgM Biosciences (Inst); Immunitas (Inst); Immunogen (Inst); Immunogen (Inst); Jacobio (Inst); Jazz Pharmaceuticals (Inst); Jounce Therapeutics (Inst); Jubilant Pharmaceuticals (Inst); Jubilant Pharmaceuticals (Inst); Lilly (Inst); Loxo (Inst); Merck (Inst); Metabomed (Inst); Mirati Therapeutics (Inst); Molecular Templates (Inst); Navire (Inst); NiKang Therapeutics (Inst); Oncorus (Inst); Poseida therapeutics (Inst); Prelude Therapeutics (Inst); PureTech (Inst); Pyramid Biosciences (Inst); Pyxis (Inst); RasCal (Inst); Regeneron (Inst); Relay Therapeutics (Inst); Rgenix (Inst); Ribon Therapeutics (Inst); Sapience Therapeutics (Inst); Sarah Cannon Research Institute (Inst); Sarah Cannon Research Institute (Inst); Seagan (Inst); Simcha Therapeutics (Inst); Sirnaomics (Inst); Stingthera (Inst); StingThera (Inst); Synthorx (Inst); Synthorx (Inst); Takeda (Inst); Takeda (Inst); Tallac Therapeutics (Inst); Tarveda Therapeutics (Inst); Teneothree (Inst); Tesaro (Inst); Turning Point Therapeutics (Inst); Xencor (Inst)
Travel, Accommodations, Expenses - HCA/Sarah Cannon (Inst)
 
Haeseong Park
Consulting or Advisory Role - Astellas Pharma; Daiichi Sankyo/UCB Japan; Merck
Research Funding - Amgen (Inst); Bolt Biotherapeutics (Inst); Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); D3Bio (Inst); Exelixis (Inst); Genentech (Inst); Huoata Bio (Inst); Idience (Inst); Incyte (Inst); Mersana (Inst); Mirati Therapeutics (Inst); Pfizer (Inst); Strata Oncology (Inst); Tizona Therapeutics, Inc. (Inst); Yuhan (Inst)
Travel, Accommodations, Expenses - Amgen
 
Rasha Cosman
No Relationships to Disclose
 
Manuel Hidalgo
Leadership - BMS; Guardant Health
Stock and Other Ownership Interests - Champions Oncology; InxMed; Nelum Corp.
Honoraria - Champions Oncology; Velavigo; Velavigo
Consulting or Advisory Role - InxMed; Oncomatrix
Research Funding - Incyte; Ranok Therapeutics; TopAl
Patents, Royalties, Other Intellectual Property - Royalties from Myriad for PALB2 patent
Travel, Accommodations, Expenses - BMS; Guardant Health
 
Davide Melisi
Consulting or Advisory Role - Baxter; Evotec; Incyte; iOnctura; Lilly
Research Funding - Celgene; Incyte; iOnctura; Roche; Shire
 
Ben Markman
Consulting or Advisory Role - AstraZeneca; Greywolf Therapeutics
 
Shigehisa Kitano
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo; Eisai; GlaxoSmithKline; Janssen; Lilly Japan; Merck KGaA; MSD; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Chugai Pharma; GlaxoSmithKline; ImmuniT Research Inc.; Kyowa Kirin; Ono Pharmaceutical; Rakuten Medical; Sumitomo Dainippon Pharma; United Immunity
Research Funding - Abbvie (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Boehringer Ingelheim (Inst); Chugai Pharma (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Daiichi Sankyo (Inst); Eisai (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Kyowa Kirin; Loxo/Lilly (Inst); Merck KGaA; MSD (Inst); Ono Pharmaceutical (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Takara Bio (Inst); Takeda (Inst)
 
Antoine Hollebecque
Honoraria - Amgen; BMS; Eisai; Incyte; MSD Oncology; Relay Therapeutics; SERVIER
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca/MedImmune (Inst); Debiopharm Group (Inst); Gritstone Bio; Incyte (Inst); Lilly (Inst); QED therapeutics; Relay Therapeutics; Sanofi; Spectrum Pharmaceuticals (Inst); Taiho Oncology; Taiho Pharmaceutical
Research Funding - AstraZeneca/MedImmune (Inst)
Travel, Accommodations, Expenses - Amgen; AstraZeneca/MedImmune; Incyte; Lilly; Pierre Fabre; Roche; SERVIER
Other Relationship - Abbvie; Agios; Amgen; argenx; Arno Therapeutics; Astex Pharmaceuticals; AstraZeneca; AVEO; Bayer; Blueprint Medicines; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Chugai Pharma; Clovis Oncology; Daiichi Sankyo; Debiopharm Group; Eisai; Exelixis; FORMA Therapeutics; GamaMabs Pharma; Genentech; GlaxoSmithKline; H3 Biomedicine; Innate Pharma; Janssen-Cilag; Kyowa Hakko Kirin; Lilly; Loxo; Lytix Biopharma; MedImmune; Menarini; Merck Sharp & Dohme; Merrimack; Merus; Millenium Pharamceuticals; Nanobiotix; Nektar; Novartis; Octimet; Oncoethix; Onyx; Orion; Oryzon Genomics; Pfizer; Pierre Fabre; Roche; Roche/Genentech; Sanofi/Aventis; SERVIER; Taiho Pharmaceutical; Tesaro; Xencor
 
Erick Saldanha
No Relationships to Disclose
 
Sabine Tejpar
Consulting or Advisory Role - Agenus; Boehringer Ingelheim; GlaxoSmithKline
Speakers' Bureau - Bristol-Myers Squibb; Merck Serono; MSD; Roche; Sanofi
Research Funding - BMS GmbH & Co. KG; GlaxoSmithKline
Travel, Accommodations, Expenses - Amgen; Bayer; Merck Serono; Roche; Sanofi
 
Philippe Cassier
Honoraria - Merck; Pierre Fabre; SERVIER
Consulting or Advisory Role - Boehringer Ingelheim; Brenus Pharma; Bristol-Myers Squibb/Celgene; Grey Wolf Therapeutics; MabQuest; OSE Immunotherapeutics; Scenic Biotech; START
Research Funding - Abbvie (Inst); Adlai Nortye (Inst); Alligator Bioscience (Inst); Amgen (Inst); AstraZeneca (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); C4 Therapeutics (Inst); Daiichi Sankyo/UCB Japan (Inst); Debiopharm Group (Inst); Dragonfly Therapeutics (Inst); Exelixis (Inst); GlaxoSmithKline (Inst); Grey Wolf Therapeutics (Inst); Incyte (Inst); Innate Pharma (Inst); ITeos Therapeutics (Inst); Janssen (Inst); Kazia Therapeutics (Inst); Kinnate Biopharma (Inst); Lilly (Inst); Loxo (Inst); MABQUEST (Inst); Merck Sharp & Dohme (Inst); Molecular Partners (Inst); Novartis (Inst); OnKure (Inst); OSE Immunotherapeutics (Inst); Pierre Fabre (Inst); Regeneron (Inst); Relay Therapeutics (Inst); Roche/Genentech (Inst); Sotio (Inst); Taiho Pharmaceutical (Inst); Tango Therapeutics (Inst); Toray Industries (Inst); Transgene (Inst)
Travel, Accommodations, Expenses - Novartis; OSE Immunotherapeutics; Pierre Fabre
(OPTIONAL) Uncompensated Relationships - ReACT Therapeutics
 
Lipika Goyal
Consulting or Advisory Role - Abbvie; Alentis Therapeutics; AstraZeneca; Black Diamond Therapeutics; Blueprint Medicines; Cogent Biosciences; Compass Therapeutics; Eisai/H3 Biomedicine; Exelixis; Genentech; Kinnate Biopharma; Merck; QED Therapeutics; Revolution Medicines; SERVIER; Sirtex Medical; Surface Oncology; Synthekine; Taiho Pharmaceutical; TransThera Biosciences; Tyra Biosciences
Research Funding - Alyssum (Inst); Genentech (Inst)
(OPTIONAL) Uncompensated Relationships - Agios; Boehringer Ingelheim; Boehringer Ingelheim; Debiopharm Group; Merck; Taiho Pharmaceutical
 
Shubham Pant
Stock and Other Ownership Interests - Teleprian
Consulting or Advisory Role - Alligator Bioscience; Arcus Biosciences; AskGene Pharma; AstraZeneca; Boehringer Ingelheim; BPGbio; Ipsen; Janssen; Jazz Pharmaceuticals; Merck; Nihon Medi-Physics; Novartis; Pfizer; Revolution Medicines; US WorldMeds
Research Funding - 4D Pharma (Inst); Amal Therapeutics (Inst); Arcus Biosciences (Inst); Astellas Pharma (Inst); bionte (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Elicio Therapeutics (Inst); Immuneering (Inst); ImmunoMET (Inst); Ipsen (Inst); Janssen (Inst); Lilly (Inst); Mirati Therapeutics (Inst); NGM Biopharmaceuticals (Inst); Novartis (Inst); Pfizer (Inst); Purple Biotech (Inst); Rgenix (Inst); Xencor (Inst); Zymeworks (Inst)
 
Amanda McBride
Employment - Incyte
Stock and Other Ownership Interests - Incyte
 
Linda Favre-Kontula
Employment - Incyte
Stock and Other Ownership Interests - Incyte
 
Mi Zhou
Employment - Incyte
Stock and Other Ownership Interests - Incyte
 
Aidan Gilmartin
Employment - Incyte
Stock and Other Ownership Interests - Incyte
 
Xiaohua Gong
Employment - Incyte
Stock and Other Ownership Interests - Incyte
 
Jayesh Desai
Consulting or Advisory Role - Amgen (Inst); Axelia Oncology; Bayer; BeiGene; Boehringer Ingelheim; Daiichi Sankyo Europe GmbH; Ellipses Pharma; GlaxoSmithKline; Incyte; Merck KGaA; Novartis; Pfizer; Pierre Fabre; Roche/Genentech
Research Funding - Amgen (Inst); AstraZeneca/MedImmune (Inst); BeiGene (Inst); Bristol-Myers Squibb (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Novartis (Inst); Roche (Inst)